Back

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study

19 June 2026 (14:15 - 15:15)
Organised by: Logo
Congress Presentation Part of: Immune-mediated cardiovascular toxicity: from early detection to real-world evidence Cardio-Oncology Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Miss Anniek Strijdhorst

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

9 More presentations in this session

Presentation thumbnail
Clinical significance of early asymptomatic high-sensitivity troponin T elevation in patients receiving immune checkpoint inhibitors
Doctor M. Akagi (Kumamoto, JP)
Abstract Slides
Presentation thumbnail
Early subclinical myocardial, vascular and endothelial dysfunction in cancer patients treated with immune checkpoint inhibitors
Doctor E. Karamanolis (Athens, GR)
Abstract Slides
Presentation thumbnail
Glucocorticoid resistant ICI associated myocarditis is defined by an interferon gamma driven myeloid inflammatory signature
Doctor J. Brauer (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Cardiac troponin identifies immune checkpoint inhibitor associated myocarditis and stratifies cardiovascular risk a systematic review and meta analysis
Mr A. Alfehaid (KW)
Abstract Slides
Presentation thumbnail
Cardiac rhythm disorders as cardiovascular toxicity of immune checkpoint inhibitors therapy: incidence and prognostic value
Doctor D. Vlachopoulou (Essen, DE)
Abstract Slides

Access the full session

Session thumbnail
Immune-mediated cardiovascular toxicity: from early detection to real-world evidence

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 14:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources